Caen Cedex 9

• A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC Ended
  2022-503007-22-00 4 Non-small Cell Lung Cancer
• PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc … Ended
  2023-503807-27-00 4 Biliary tract carcinoma
• Impact of CardiolRxTM on Recurrent Pericarditis: An open label Pilot Study Ended
  2023-507452-77-00 3 Recurrent Pericarditis
• Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy Ended
  2023-509615-92-00 4 Ischemic stroke with Large Core
• IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reac … Ended
  2024-513887-25-00 4 AL Amyloidosis
• A clinical study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with metastatic nons … Ended
  2024-515393-27-00 4 Nonsquamous non-small cell lung cancer
• Does high-dose vitamin B3 supplementation prevent major adverse kidney events during septic shock? A multicenter randomized controlled study Ended
  2024-517055-13-00 5 adverse kidney events during septic shock

Showing 289–295 of 295 trials